Clinical Trial Update: Symptomatic Study Investigating Degarelix in Patients Suffering From Prostate Cancer [Phase 3]

View source ↗

Summary

A Phase 3 symptomatic trial of degarelix for prostate cancer sponsored by Ferring Pharmaceuticals has been terminated. Results from the study have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Firmagon (Degarelix)

Snippet

Sponsor: Ferring Pharmaceuticals | Conditions: Prostate Cancer | Phase 3 | Status: TERMINATED | Results posted: 2011-08-26